Diseases

Novel Diagnostics

CrossLife Technologies is dedicated to developing and commercializing novel diagnostics based on innovative nucleic acid technologies for many diseases.

Dengue

We provide an enzyme-free, PCR-less, instrumentation-free, low-cost, disposable, rapid and sensitive POC dengue diagnostics directly from whole blood samples.

Chikungunya

CrossLife Tech’s CHIK test will detect CHIK in 40 minutes on a paper strip at the point of care so that patients can be treated rapidly and at low cost.

Zika

There are unmet needs for nucleic acids new diagnostics that can be applied at the point-of-care to detect Zika Virus (ZIKV) infections.

Influenza

Emerging infectious diseases and pandemics in humans often originate from pathogens transmitted from nonhuman animal reservoirs. The pandemics of severe acute...

HIV

Current antibody point-of-care tests cannot distinguish between a mother’s and baby’s antibodies to detect if an infant has become infected with Human...

HCV

Approximately, 170 million people globally which are 2– 3% of the world’ s population are infected with HCV, with an estimated 2.7 to 3.9 million people infected in...